Tisotumab Vedotin Gains Full FDA Approval for Recurrent or Metastatic Cervical Cancer

The FDA granted full approval for tisotumab vedotin-tftv to treat recurrent or metastatic cervical cancer that progressed after chemotherapy, offering patients improved overall survival and a manageable safety profile.

Related Keywords

Tamika Felder ,Chris Boshoff ,Brian Slomovitz ,Pfizer ,Cervivor Inc ,Image Credit ,Cancer Research Committee ,Mount Sinai Medical Center ,Miami Beach ,Chief Visionary Officer ,Tisotumab Vedotin ,